JA
SRPT icon

JOYN Advisors’s Sarepta Therapeutics SRPT Stock Holding History

JOYN Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-373
Closed -$41K – 1220
2018
Q4 		$41K Sell
373
-117
-24% -$14.6K 0.01% 418
2018
Q3 		$79K Sell
490
-17
-3% -$2.32K 0.01% 270
2018
Q2 		$67K Sell
507
-210
-29% -$19.8K 0.01% 319
2018
Q1 		$53K Buy
+717
New +$47.8K 0.01% 439

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JOYN Advisors's SRPT Position: Q1 2019 in Review

JOYN Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2019, closing a stake of 373 shares — an estimated $41K sold.

JOYN Advisors first reported a position in SRPT in Q1 2018 and held it in 4 quarters. The position peaked at $79K in Q3 2018. 371 funds tracked by Wall St. Rank hold SRPT as of Q1 2019.

  • JOYN Advisors reported no remaining Sarepta Therapeutics position as of Q1 2019 after selling out during the quarter.
  • JOYN Advisors sold 373 Sarepta Therapeutics shares in Q1 2019, an estimated $41K.
  • JOYN Advisors first reported a position in Sarepta Therapeutics in Q1 2018 and held it in 4 quarters.
  • JOYN Advisors's Sarepta Therapeutics position peaked at $79K in Q3 2018.
  • 371 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2019.

Based on JOYN Advisors's 13F filing for Q1 2019, filed 9 May 2019.